SCHEMBL19667625

SCHEMBL19667625

CC1C(C(C)(C)C)Oc2cccc(OCc3ccccc3)c2C(=O)N1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
BRD4 O60885 3/20 0.39
CREBBP Q92793 2/20 0.39
PRKCA P17252 1/20 0.38
PTGER1 P34995 1/20 0.37
EDNRA P25101 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NAAA Q02083 3/20 0.35
NR3C1 P04150 1/20 0.35
HTT P42858 1/20 0.35
LTB4R Q15722 2/20 0.35
LTB4R2 Q9NPC1 2/20 0.35
MCL1 Q07820 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20873489 0.78 BRD4 (0.43) MAOAMAOBBRD4CREBBPPRKCA
SCHEMBL20873490 0.78 BRD4 (0.43) MAOAMAOBBRD4CREBBPPRKCA
SCHEMBL19667669 0.78 AGTR2 (0.38) BRD4PTGER1EDNRARXRARXRB
SCHEMBL19667626 0.73 BRD4 (0.41) MAOAMAOBBRD4CREBBPPRKCA
SCHEMBL19679355 0.73 MAOA (0.42) MAOAMAOBBRD4CREBBPPRKCA
SCHEMBL19667179 0.70 KDM1A (0.43) BRD4CREBBPPTGER1RXRARXRB
SCHEMBL20873521 0.64 SMN1; SMN2 (0.46) BRD4PTGER1EDNRAMAPTMAPK1
SCHEMBL20873522 0.64 SMN1; SMN2 (0.46) BRD4PTGER1EDNRAMAPTMAPK1
SCHEMBL20873484 0.64 FFAR1 (0.42) BRD4PTGER1EDNRAMAPTMAPK1
SCHEMBL20873486 0.64 FFAR1 (0.42) BRD4PTGER1EDNRAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10220037-B2 Substituted carbonucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2019-03-05 US disclosed
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP MAOA 3689/4885MAOB 3330/4885BRD4 2445/4885
US-10220037-B2 Substituted carbonucleoside derivatives useful as anticancer agents DUT, NCL, TYMP MAOA 3689/4885MAOB 3330/4885BRD4 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.